Sun Pharmaceutical Builds Specialty Growth as Organon Deal Nears Closure

Investment View and Valuation

Geojit Investments Limited’s September 21, 2026 report on Sun Pharmaceutical Industries Limited retains a BUY recommendation and raises the target price to Rs 2,070 from Rs 1,933. The target is based on 30 times FY28E adjusted earnings per share of Rs 69.0.

Geojit’s positive view rests on Sun Pharma’s expanding Innovative Medicines and specialty portfolio, continued domestic-market leadership, momentum in important international geographies and the proposed Organon acquisition.

Q1 FY27 Financial Performance

Sun Pharma reported consolidated revenue from operations of Rs 15,300 crore in Q1 FY27, up 10.5 per cent year on year and 4.7 per cent quarter on quarter. Growth was led by India formulations and sustained momentum in Innovative Medicines.

The margin moderation reflected the absence of the one-off contribution from Lenalidomide sales in Q1 FY26.

Growth Outlook and Business Drivers

Management expects high single-digit growth during FY27, led by the specialty and domestic businesses. The Global Specialty business accounted for 22 per cent of sales and delivered broad-based growth, supported by ILUMYA and ODOMZO. New launches, including Leqselvi and Unloxcyt, were gaining traction.

Sun Pharma retained leadership in the Indian pharmaceutical market with an 8.4 per cent market share. Growth in the domestic market was largely volume-led and supported by new product launches.

The report highlights semaglutide as a key future growth driver. Management cited the company’s differentiated auto-injector platform, in-house manufacturing capabilities and expansion in emerging markets including South Africa and Brazil.

Research and Development and US Generics

Sun Pharma invested Rs 826 crore, or 5.4 per cent of Q1 FY27 sales, in research and development for innovative therapies and complex product development.

In the United States generics business, the company had 558 approved ANDAs and 119 pending filings, including 28 tentative approvals. It filed three ANDAs and received six approvals during the quarter.

Proposed Organon Acquisition

Geojit sees the proposed US$11.75 billion Organon acquisition as a significant strategic driver. The transaction was progressing as planned, key approvals had been received and closure was targeted by Q4 FY27.

The acquisition is expected to broaden Sun Pharma’s global therapeutic presence through Women’s Health and Biosimilars and enhance global scale. Sun Pharma incurred Rs 167 crore of Organon-related transaction costs in Q1 FY27.

Moody’s assigned a Baa1 Stable rating and S&P assigned a BBB+ Stable rating. Management and Geojit believe these ratings should improve funding flexibility for the acquisition.

Geojit Earnings Estimates

Key Considerations for the Thesis

• Delivery of specialty-product growth.
• Domestic market-share gains.
• Semaglutide commercialisation.
• Successful completion and integration of the Organon acquisition.